A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer ; volume:41 ; number:7 ; day:2 ; month:5 ; year:2024 ; pages:2586-2605 ; date:7.2024
Advances in therapy ; 41, Heft 7 (2.5.2024), 2586-2605, 7.2024
- Creator
-
Baik, Christina
Cheng, Michael L.
Dietrich, Martin
Gray, Jhanelle E.
Karim, Nagla A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02839-4
- URN
-
urn:nbn:de:101:1-2409230948005.988779083718
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Baik, Christina
- Cheng, Michael L.
- Dietrich, Martin
- Gray, Jhanelle E.
- Karim, Nagla A.
- SpringerLink (Online service)
Other Objects (12)
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
Concurrent involvement of the bone marrow by BRAF V600E–mutant melanoma and hairy cell leukemia
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
BRAF V600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
BRAF V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells